DEF: The Joint Corp. Reports 2025 Progress and Outlines Future Growth

The Joint Corp. announces a return to profitability in 2025 with $2.9 million net income and 13.9% Adjusted EBITDA growth, driven by refranchising efforts and strategic initiatives.

Summary

• The Joint Corp. reported a significant turnaround in 2025, achieving profitability with a net income of $2.9 million, a substantial improvement from a $5.8 million net loss in the prior year.
• Consolidated revenue increased by 5.2% to $54.9 million in 2025, up from $52.2 million in 2024.
• Consolidated Adjusted EBITDA grew by 13.9% to $13.0 million in 2025, compared to $11.4 million in 2024.
• System-wide sales saw a modest increase of 0.4% to $532.4 million in 2025.
• The company repurchased 1.3 million common shares for $11.3 million during 2025.
• The company is nearing completion of its refranchising initiative, with only 48 company-owned or managed clinics remaining.
• New clinic openings in 2025 achieved breakeven in half the time compared to prior years.
• The company is developing 'Joint 3.0', a future growth phase focusing on new geographic markets, B2B channels, and potential international expansion, set to begin in 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the return to profitability, strong Adjusted EBITDA growth, and clear strategic direction towards a more efficient franchise model, despite some minor declines in patient numbers and franchise sales.

Positives

• Return to profitability with a net income of $2.9 million in 2025, a significant improvement from a net loss in 2024.
• 13.9% increase in Consolidated Adjusted EBITDA to $13.0 million in 2025.
• Consolidated revenue grew by 5.2% to $54.9 million in 2025.
• Successful progress on refranchising initiative, reducing company-owned clinics to 5% of the total base.
• New clinics opened in 2025 reached breakeven in half the time compared to previous years.
• 1.3 million common shares repurchased for $11.3 million, demonstrating commitment to returning capital to shareholders.
• Improved marketing approach and SEO leading to better website traffic and organic leads.
• Strategic shift towards a pure-play franchisor model is expected to result in a more efficient, higher-margin business with strong cash flow.

Negatives

• System-wide sales increased by only 0.4% to $532.4 million in 2025.
• Comparable store sales decreased by 0.4% in 2025.
• Number of unique patients treated decreased to 1.7 million in 2025 from 1.9 million in 2024.
• Number of franchise licenses sold decreased to 31 in 2025 from 57 in 2024.

Risks

• Inability to identify and recruit enough qualified chiropractors and other personnel due to labor shortages.
• Inflation leading to increased labor costs and interest rates, potentially reducing discretionary spending.
• Failure to profitably operate remaining company-owned or managed clinics.
• Failure to complete the refranchising plan as anticipated.
• Short-selling strategies and negative online sentiment potentially driving down stock price and leading to lawsuits.
• Failure to remediate future material weaknesses in internal control over financial reporting.
• Risks associated with the transition to a pure-play franchisor model.
• Potential impact of changes to import tariffs on business.

Future Outlook

The company expects to complete its transition to a pure-play franchisor by the end of 2026, leading to a structurally improved financial profile with an estimated revenue run rate of 11% of system-wide sales and an Adjusted EBITDA margin run rate of 19% to 21%. The company is also developing 'Joint 3.0', a growth strategy for 2027 focusing on new markets, B2B channels, and international expansion, leveraging trends in longevity and non-invasive care.

Management Comments

• "Over the last year and a half, I have had the opportunity to work closely with a talented team that is deeply committed to our patients, franchisees, and stockholders and to advancing our model of convenient, membership-based chiropractic care in accessible retail settings."
• "That experience has strengthened my conviction in the quality of our people, the resilience of our business model, and the scale of the opportunity in front of us."
• "I am confident that more improvement is ahead of us."
• "By the end of 2026, we expect to have a streamlined, more profitable business that generates robust cash flow. Beyond that, Joint 3.0 gives us room to grow into new markets, new channels, and new services."

Industry Context

StockSavvy.ai notes that The Joint Corp.'s strategic shift towards a pure-play franchisor model aligns with industry trends favoring asset-light business structures that can yield higher margins and stronger cash flow. The company's focus on convenience and membership-based care addresses growing consumer interest in accessible wellness solutions.

Comparison to Industry Standards

• The Joint Corp.'s 15-year CAGR of 38% significantly outpaces the industry's 5-year CAGR of 2% for Chiropractics in the U.S. (as per IBISWorld report October 2025).
• The company's projected post-refranchising Adjusted EBITDA margin of 19% to 21% is a substantial improvement, aiming to reach industry-leading levels for asset-light franchise models.
• The company's focus on membership-based recurring revenue (85% of revenue) is a strong model within the health and wellness sector, often leading to higher customer lifetime value compared to transactional models.

Corporate Governance

Related Party Transactions

• Jefferson Gramm, a significant shareholder and director, is affiliated with Bandera Partners LLC. The company has entered into an Amended Nomination and Standstill Agreement and a Letter Agreement with Bandera and Mr. Gramm, outlining nomination rights and stock acquisition restrictions.
• In 2020 and 2021, franchise licenses were sold to Marshall Gramm (family member of Jefferson Gramm) and a franchisee where Jefferson Gramm was a 50% co-partner. Mr. Gramm divested his interest in the latter in Q4 2024. These transactions were on terms no less favorable than arm's length.
• In October 2020, Mr. Gramm loaned approximately $370,000 to an unaffiliated franchisee; the remaining balance was $196,000 as of December 31, 2025.

Stakeholder Impact

• Shareholders: The return to profitability and strategic shift to a higher-margin model are expected to enhance shareholder value. Share repurchases also benefit shareholders.
• Franchisees: Marketing, SEO, and pricing initiatives are intended to support franchisees by improving new patient acquisition and retention, leading to system-wide sales and royalty growth.
• Employees: The company's focus on growth and efficiency may lead to opportunities, though specific impacts are not detailed.
• Patients: Continued focus on convenient, membership-based chiropractic care aims to meet patient needs for pain relief and wellness.

Next Steps

• Complete refranchising initiative by the end of 2026.
• Continue to tighten costs and invest in marketing and pricing strategies.
• Develop and implement 'Joint 3.0' strategy starting in 2027, focusing on new geographic markets, B2B channels, and international expansion.
• Hold the 2026 Annual Meeting of Stockholders on May 20, 2026.
• Stockholders to vote on director elections, executive compensation, and ratification of the independent auditor.

Key Dates

Recommendation

The company has demonstrated a positive turnaround with a return to profitability and strategic progress in refranchising. However, the modest growth in system-wide sales and comparable store sales, along with a decrease in unique patients, suggests that while the company is on the right track, significant growth catalysts are still in the future ('Joint 3.0'). The current valuation should be monitored as the company executes its long-term strategy.

Keywords

The Joint Corp, Proxy Statement, Annual Meeting, Executive Compensation, Director Election, Financial Results, Refranchising, Chiropractic Care, Franchise Model, Adjusted EBITDA, Net Income